Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pulmonary Hypertension REversal 6-Mercaptopurine Proof-of-Concept Trial
2017-000137-31Phase 2Terminated
- Sponsor
- VU University Medical Center
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of mercaptopurine in pulmonary arterial hypertension (PAH), sponsored by VU University Medical Center. Primary endpoint: Pulmonary vascular resistance. Started Jul 2017; status: terminated.
02
Drugs
mercaptopurine
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2017-000137-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000137-31.